+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Critical Limb Ischemia Treatment Market by Treatment Modality, Device Type, End User, Distribution Channel - Global Forecast to 2030- Product Image
Critical Limb Ischemia Treatment Market by Treatment Modality, Device Type, End User, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Critical Limb Ischemia Treatment Market by Treatment Modality, Device Type, End User, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 180 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5967998
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Critical Limb Ischemia Treatment Market grew from USD 4.46 billion in 2024 to USD 4.87 billion in 2025. It is expected to continue growing at a CAGR of 8.94%, reaching USD 7.45 billion by 2030.

Understanding the Critical Limb Ischemia Challenge

Critical limb ischemia represents the most severe manifestation of peripheral artery disease, imposing a profound clinical and economic burden globally. Patients face nonstop risk of tissue loss, chronic pain, and amputation when blood flow to lower extremities deteriorates. Meanwhile, healthcare systems grapple with escalating hospitalization rates, complex wound management, and the need for multidisciplinary interventions. Given this backdrop, decision-makers across clinical, manufacturing, and policy spheres require a panoramic view of evolving treatment paradigms, emerging technologies, and market forces.

This executive summary synthesizes critical insights across innovation trajectories, tariff impacts, segmentation dynamics, and regional nuances. It sets the stage for evidence-based strategy development by spotlighting key players, evaluating drivers of adoption, and pinpointing future growth catalysts. By presenting a concise yet comprehensive overview, we aim to empower medical device executives, clinical thought leaders, and investors with the knowledge to navigate complexity and spearhead advances in patient care.

Emerging Paradigm Shifts Redefining Treatment Standards

The past decade has witnessed a fundamental reorientation of critical limb ischemia management, driven by breakthroughs in minimally invasive procedures, pharmacologic regimens, and digital health integration. Endovascular techniques now extend far beyond simple balloon angioplasty, as advanced atherectomy modalities and next-generation stents deliver superior lesion coverage and reduced restenosis rates. Pharmacotherapy has evolved with the advent of novel antiplatelet agents and targeted vasodilators that optimize microvascular perfusion, while supportive care protocols employ hyperbaric oxygen and advanced wound dressings to accelerate healing.

Simultaneously, care pathways have become increasingly patient-centric, combining telemonitoring with personalized rehabilitation programs. The convergence of data analytics, wearable sensors, and remote consultation fosters early detection of ulceration risk and real-time therapy adjustments. These transformative shifts are redefining clinical guidelines and reimbursement frameworks, compelling stakeholders to reassess investment priorities and forge new partnerships. As treatment benchmarks rise, the industry stands at a crossroads where collaboration across device innovators, pharmaceutical companies, and care networks will determine the next wave of therapeutic breakthroughs.

Assessing the 2025 US Tariff Implications on Treatment Pathways

With the United States implementing revised tariffs on select medical devices and components in 2025, cost structures across critical limb ischemia therapies will come under intensified scrutiny. Protective measures on imported balloons, stents, graft materials, and embolic protection systems may translate into price adjustments that reverberate through procurement budgets of hospitals and surgery centers. Manufacturers could respond by reshoring production or reengineering device designs to incorporate domestically sourced polymers and metals.

Projected tariff-related cost uplifts may influence clinicians’ device selection, with a possible pivot toward lower-cost alternatives or increased preference for combination pharmacotherapy where feasible. Supply chain strategies will need realignment, as distributors and third-party logistics providers diversify sourcing regions to mitigate duty exposure. Ultimately, the tariff landscape presents both challenges and incentives: while near-term margin pressures may arise, domestic manufacturing expansion offers opportunities for faster lead times, closer quality control, and stronger alignment with U.S. regulatory requirements.

Unveiling Market Dynamics Across Treatment, Device and End User Profiles

The critical limb ischemia market can be parsed across treatment modality, device type, end user and distribution channel, each offering unique vantage points. Treatment pathways span endovascular procedures, pharmacotherapy, supportive care and surgical interventions. Endovascular approaches further break down into angioplasty techniques that include drug coated balloon and plain old balloon, atherectomy methods such as directional, laser, orbital and rotational, and stenting through bare metal and drug eluting variants. Pharmacotherapy encompasses antiplatelet agents, thrombolytics and vasodilators, while supportive care integrates hyperbaric oxygen therapy, pain management and advanced wound care. Surgical procedures pivot on endarterectomy or bypass surgery, the latter distinguished by autologous vein graft and synthetic graft options.

From the device perspective, the market covers atherectomy devices, balloons, embolic protection units, stents and vascular grafts. Atherectomy technology again splits into directional, laser, orbital and rotational variants, while balloon devices feature both drug coated and plain old options. Embolic protection ranges from distal filters to proximal occlusion balloons. Stent offerings extend across bare metal, covered and drug eluting platforms, and vascular grafts utilize autologous vein or synthetic graft material. End users include ambulatory surgery centers, hospitals and specialty vascular centers, each further categorized by ownership or operational model. Distribution flows through direct sales channels, hospital pharmacies-both inpatient and outpatient settings-and third party distributors, including retail pharmacies and wholesale partners.

Regional Trends Shaping Critical Limb Ischemia Care Worldwide

Across the Americas, investment in advanced endovascular infrastructure and supportive care protocols continues to accelerate, driven by high incidence rates and favorable reimbursement frameworks. Clinicians in North America leverage integrated care models that combine interventional radiology, vascular surgery and specialized wound clinics to optimize limb salvage rates. Latin American markets are gaining momentum as regional manufacturing partnerships increase access to cost-effective devices and training programs enhance procedural expertise.

In Europe, Middle East and Africa, reimbursement pathways vary significantly, but the demand for minimally invasive solutions remains strong. Western Europe’s established healthcare systems support the adoption of drug eluting stents and atherectomy platforms, while emerging markets in EMEA prioritize scalable pharmacotherapy and wound care therapies. Gulf Cooperation Council countries are investing heavily in specialized vascular centers, and North African nations are expanding hyperbaric oxygen facilities to complement pharmacologic regimens.

Asia-Pacific presents a diverse landscape. Japan and Australia spearhead technology adoption through rigorous clinical validation, while China and India focus on localizing production and fostering public-private collaborations to drive down costs. Southeast Asian nations invest in telehealth and digital wound assessment tools to overcome geographic barriers. Across all regions, regulatory harmonization efforts and cross-border clinical trials are shaping a more interconnected global market.

Competitive Landscape Highlights Pioneering Solutions

The competitive arena is defined by global medical device leaders and nimble innovators alike. Established corporations are expanding their portfolios through strategic acquisitions and platform enhancements, ensuring broad coverage across angioplasty balloons, stents, atherectomy devices and vascular grafts. Emphasis on next-generation drug elution and biocompatible polymers underscores a push toward sustained vessel patency and reduced restenosis.

Simultaneously, emerging players are carving niches with disruptive technologies such as biodegradable scaffolds and digital diagnostics that enable lesion morphology assessment in real time. Partnerships between device manufacturers and pharmaceutical innovators are fostering combination therapy trials that pair localized drug delivery with mechanical intervention for synergistic efficacy. Companies prioritizing robust clinical data and health economics evidence are gaining traction with payers and health systems, while those investing in physician training programs and patient support services are cultivating deeper market access.

Strategic Imperatives for Industry Leaders to Enhance Outcomes

Industry leaders should prioritize integration of advanced endovascular platforms with targeted pharmacotherapies to maximize clinical efficacy and economic value. Establishing flexible manufacturing networks that can pivot between domestic and offshore production will mitigate tariff exposure and safeguard supply continuity. Engaging payers early with real-world evidence on limb salvage outcomes, cost of care reduction and quality-of-life improvements will streamline reimbursement approvals.

Collaborative initiatives with key opinion leaders and specialty vascular centers will strengthen clinical adoption, while investment in telemonitoring and digital wound assessment tools can enhance patient adherence and early complication detection. Manufacturers should consider modular device designs that accommodate emerging materials, ensuring rapid iteration in response to evolving regulatory standards. Finally, creating multidisciplinary educational programs for interventionalists, vascular surgeons and wound care specialists will accelerate best-practice dissemination and reinforce brand leadership.

Robust Analytical Framework Underpinning the Insights

Our research methodology combined extensive secondary research with targeted primary interviews to construct a holistic view of the critical limb ischemia market. Peer-reviewed journals, regulatory filings, company publications and clinical trial databases formed the backbone of secondary data collection. In parallel, one-on-one interviews with interventional cardiologists, vascular surgeons, hospital procurement managers and payers yielded nuanced perspectives on treatment preferences, budgetary constraints and emerging needs.

Data was triangulated using cross-validation techniques to ensure consistency and reliability. Segmentation frameworks were applied to dissect the market by treatment modality, device type, end user and distribution channel. Regional analyses incorporated epidemiological data, reimbursement policies and infrastructural readiness. Quality control processes, including peer review and editorial oversight, were employed at each research stage to uphold accuracy and impartiality.

Synthesizing Insights to Navigate Future Opportunities

In synthesizing these insights, the critical limb ischemia landscape emerges as a dynamic interplay of technological innovation, policy influences and evolving clinical paradigms. Stakeholders who anticipate tariff-driven cost shifts and strategically realign sourcing will gain competitive advantage. Firms that invest in endovascular-pharmacotherapy synergies and leverage digital health for patient engagement will set new standards of care.

Regional disparities present both challenges and growth prospects, with developed markets offering rapid adoption pathways and emerging regions unveiling unmet needs. The convergence of data analytics, next-generation materials and patient-centric models heralds a new era of personalized ischemia management. As we move forward, sustained collaboration between device innovators, pharmaceutical companies, healthcare providers and policymakers will be essential to improve limb salvage rates and enhance patient quality of life.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Modality
    • Endovascular Procedures
      • Angioplasty
        • Drug Coated Balloon
        • Plain Old Balloon
      • Atherectomy
        • Directional Atherectomy
        • Laser Atherectomy
        • Orbital Atherectomy
        • Rotational Atherectomy
      • Stenting
        • Bare Metal Stent
        • Drug Eluting Stent
    • Pharmacotherapy
      • Antiplatelet Agents
      • Thrombolytics
      • Vasodilators
    • Supportive Care
      • Hyperbaric Oxygen Therapy
      • Pain Management
      • Wound Care
    • Surgical Procedures
      • Bypass Surgery
        • Autologous Vein Graft
        • Synthetic Graft
      • Endarterectomy
  • Device Type
    • Atherectomy Devices
      • Directional Atherectomy
      • Laser Atherectomy
      • Orbital Atherectomy
      • Rotational Atherectomy
    • Balloons
      • Drug Coated Balloon
      • Plain Old Balloon
    • Embolic Protection Devices
      • Distal Filter
      • Proximal Occlusion Balloon
    • Stents
      • Bare Metal Stent
      • Covered Stent
      • Drug Eluting Stent
    • Vascular Grafts
      • Autologous Vein Graft
      • Synthetic Graft
  • End User
    • Ambulatory Surgery Centers
      • Hospital Owned Centers
      • Standalone Centers
    • Hospitals
      • Private Hospitals
      • Public Hospitals
    • Specialty Vascular Centers
      • Hospital Owned Centers
      • Independent Centers
  • Distribution Channel
    • Direct Sales
    • Hospital Pharmacies
      • Inpatient
      • Outpatient
    • Third Party Distributors
      • Retail Pharmacies
      • Wholesale Distributors
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Boston Scientific Corporation
  • Medtronic plc
  • Abbott Laboratories
  • LimFlow SA
  • Terumo Corporation
  • Cynata Therapeutics Ltd
  • Becton, Dickinson and Company
  • Penumbra, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Critical Limb Ischemia Treatment Market, by Treatment Modality
8.1. Introduction
8.2. Endovascular Procedures
8.2.1. Angioplasty
8.2.1.1. Drug Coated Balloon
8.2.1.2. Plain Old Balloon
8.2.2. Atherectomy
8.2.2.1. Directional Atherectomy
8.2.2.2. Laser Atherectomy
8.2.2.3. Orbital Atherectomy
8.2.2.4. Rotational Atherectomy
8.2.3. Stenting
8.2.3.1. Bare Metal Stent
8.2.3.2. Drug Eluting Stent
8.3. Pharmacotherapy
8.3.1. Antiplatelet Agents
8.3.2. Thrombolytics
8.3.3. Vasodilators
8.4. Supportive Care
8.4.1. Hyperbaric Oxygen Therapy
8.4.2. Pain Management
8.4.3. Wound Care
8.5. Surgical Procedures
8.5.1. Bypass Surgery
8.5.1.1. Autologous Vein Graft
8.5.1.2. Synthetic Graft
8.5.2. Endarterectomy
9. Critical Limb Ischemia Treatment Market, by Device Type
9.1. Introduction
9.2. Atherectomy Devices
9.2.1. Directional Atherectomy
9.2.2. Laser Atherectomy
9.2.3. Orbital Atherectomy
9.2.4. Rotational Atherectomy
9.3. Balloons
9.3.1. Drug Coated Balloon
9.3.2. Plain Old Balloon
9.4. Embolic Protection Devices
9.4.1. Distal Filter
9.4.2. Proximal Occlusion Balloon
9.5. Stents
9.5.1. Bare Metal Stent
9.5.2. Covered Stent
9.5.3. Drug Eluting Stent
9.6. Vascular Grafts
9.6.1. Autologous Vein Graft
9.6.2. Synthetic Graft
10. Critical Limb Ischemia Treatment Market, by End User
10.1. Introduction
10.2. Ambulatory Surgery Centers
10.2.1. Hospital Owned Centers
10.2.2. Standalone Centers
10.3. Hospitals
10.3.1. Private Hospitals
10.3.2. Public Hospitals
10.4. Specialty Vascular Centers
10.4.1. Hospital Owned Centers
10.4.2. Independent Centers
11. Critical Limb Ischemia Treatment Market, by Distribution Channel
11.1. Introduction
11.2. Direct Sales
11.3. Hospital Pharmacies
11.3.1. Inpatient
11.3.2. Outpatient
11.4. Third Party Distributors
11.4.1. Retail Pharmacies
11.4.2. Wholesale Distributors
12. Americas Critical Limb Ischemia Treatment Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Critical Limb Ischemia Treatment Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Critical Limb Ischemia Treatment Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Boston Scientific Corporation
15.3.2. Medtronic plc
15.3.3. Abbott Laboratories
15.3.4. LimFlow SA
15.3.5. Terumo Corporation
15.3.6. Cynata Therapeutics Ltd
15.3.7. Becton, Dickinson and Company
15.3.8. Penumbra, Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. CRITICAL LIMB ISCHEMIA TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. CRITICAL LIMB ISCHEMIA TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. CRITICAL LIMB ISCHEMIA TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DEVICE TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DEVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. CRITICAL LIMB ISCHEMIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. CRITICAL LIMB ISCHEMIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CRITICAL LIMB ISCHEMIA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ENDOVASCULAR PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ANGIOPLASTY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DRUG COATED BALLOON, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PLAIN OLD BALLOON, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ANGIOPLASTY, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DIRECTIONAL ATHERECTOMY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY LASER ATHERECTOMY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ORBITAL ATHERECTOMY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ROTATIONAL ATHERECTOMY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BARE METAL STENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DRUG ELUTING STENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTING, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ENDOVASCULAR PROCEDURES, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ANTIPLATELET AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY VASODILATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HYPERBARIC OXYGEN THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY WOUND CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BYPASS SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY AUTOLOGOUS VEIN GRAFT, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SYNTHETIC GRAFT, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BYPASS SURGERY, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ENDARTERECTOMY, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DIRECTIONAL ATHERECTOMY, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY LASER ATHERECTOMY, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ORBITAL ATHERECTOMY, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ROTATIONAL ATHERECTOMY, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY DEVICES, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BALLOONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DRUG COATED BALLOON, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PLAIN OLD BALLOON, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BALLOONS, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DISTAL FILTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PROXIMAL OCCLUSION BALLOON, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BARE METAL STENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COVERED STENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DRUG ELUTING STENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTS, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY AUTOLOGOUS VEIN GRAFT, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SYNTHETIC GRAFT, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HOSPITAL OWNED CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STANDALONE CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SPECIALTY VASCULAR CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HOSPITAL OWNED CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY INDEPENDENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SPECIALTY VASCULAR CENTERS, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY INPATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 83. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 84. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 85. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY WHOLESALE DISTRIBUTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 86. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ENDOVASCULAR PROCEDURES, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ANGIOPLASTY, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTING, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BYPASS SURGERY, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY DEVICES, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BALLOONS, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTS, 2018-2030 (USD MILLION)
TABLE 101. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, 2018-2030 (USD MILLION)
TABLE 102. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 103. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, 2018-2030 (USD MILLION)
TABLE 104. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 105. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SPECIALTY VASCULAR CENTERS, 2018-2030 (USD MILLION)
TABLE 106. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 107. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 108. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 109. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 110. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 111. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ENDOVASCULAR PROCEDURES, 2018-2030 (USD MILLION)
TABLE 112. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ANGIOPLASTY, 2018-2030 (USD MILLION)
TABLE 113. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY, 2018-2030 (USD MILLION)
TABLE 114. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTING, 2018-2030 (USD MILLION)
TABLE 115. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 116. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 117. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 118. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BYPASS SURGERY, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY DEVICES, 2018-2030 (USD MILLION)
TABLE 121. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BALLOONS, 2018-2030 (USD MILLION)
TABLE 122. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2030 (USD MILLION)
TABLE 123. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTS, 2018-2030 (USD MILLION)
TABLE 124. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, 2018-2030 (USD MILLION)
TABLE 125. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, 2018-2030 (USD MILLION)
TABLE 127. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 128. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SPECIALTY VASCULAR CENTERS, 2018-2030 (USD MILLION)
TABLE 129. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 131. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 132. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 133. CANADA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 134. CANADA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ENDOVASCULAR PROCEDURES, 2018-2030 (USD MILLION)
TABLE 135. CANADA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ANGIOPLASTY, 2018-2030 (USD MILLION)
TABLE 136. CANADA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY, 2018-2030 (USD MILLION)
TABLE 137. CANADA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTING, 2018-2030 (USD MILLION)
TABLE 138. CANADA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 139. CANADA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 140. CANADA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 141. CANADA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BYPASS SURGERY, 2018-2030 (USD MILLION)
TABLE 142. CANADA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 143. CANADA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY DEVICES, 2018-2030 (USD MILLION)
TABLE 144. CANADA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BALLOONS, 2018-2030 (USD MILLION)
TABLE 145. CANADA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2030 (USD MILLION)
TABLE 146. CANADA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTS, 2018-2030 (USD MILLION)
TABLE 147. CANADA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, 2018-2030 (USD MILLION)
TABLE 148. CANADA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. CANADA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, 2018-2030 (USD MILLION)
TABLE 150. CANADA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 151. CANADA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SPECIALTY VASCULAR CENTERS, 2018-2030 (USD MILLION)
TABLE 152. CANADA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. CANADA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 154. CANADA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 155. MEXICO CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 156. MEXICO CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ENDOVASCULAR PROCEDURES, 2018-2030 (USD MILLION)
TABLE 157. MEXICO CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ANGIOPLASTY, 2018-2030 (USD MILLION)
TABLE 158. MEXICO CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY, 2018-2030 (USD MILLION)
TABLE 159. MEXICO CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTING, 2018-2030 (USD MILLION)
TABLE 160. MEXICO CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 161. MEXICO CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 162. MEXICO CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 163. MEXICO CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BYPASS SURGERY, 2018-2030 (USD MILLION)
TABLE 164. MEXICO CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 165. MEXICO CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY DEVICES, 2018-2030 (USD MILLION)
TABLE 166. MEXICO CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BALLOONS, 2018-2030 (USD MILLION)
TABLE 167. MEXICO CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2030 (USD MILLION)
TABLE 168. MEXICO CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTS, 2018-2030 (USD MILLION)
TABLE 169. MEXICO CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, 2018-2030 (USD MILLION)
TABLE 170. MEXICO CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. MEXICO CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, 2018-2030 (USD MILLION)
TABLE 172. MEXICO CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 173. MEXICO CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SPECIALTY VASCULAR CENTERS, 2018-2030 (USD MILLION)
TABLE 174. MEXICO CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 175. MEXICO CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 176. MEXICO CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 177. BRAZIL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 178. BRAZIL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ENDOVASCULAR PROCEDURES, 2018-2030 (USD MILLION)
TABLE 179. BRAZIL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ANGIOPLASTY, 2018-2030 (USD MILLION)
TABLE 180. BRAZIL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY, 2018-2030 (USD MILLION)
TABLE 181. BRAZIL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTING, 2018-2030 (USD MILLION)
TABLE 182. BRAZIL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 183. BRAZIL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 184. BRAZIL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 185. BRAZIL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BYPASS SURGERY, 2018-2030 (USD MILLION)
TABLE 186. BRAZIL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 187. BRAZIL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY DEVICES, 2018-2030 (USD MILLION)
TABLE 188. BRAZIL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BALLOONS, 2018-2030 (USD MILLION)
TABLE 189. BRAZIL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2030 (USD MILLION)
TABLE 190. BRAZIL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTS, 2018-2030 (USD MILLION)
TABLE 191. BRAZIL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, 2018-2030 (USD MILLION)
TABLE 192. BRAZIL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 193. BRAZIL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, 2018-2030 (USD MILLION)
TABLE 194. BRAZIL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 195. BRAZIL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SPECIALTY VASCULAR CENTERS, 2018-2030 (USD MILLION)
TABLE 196. BRAZIL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. BRAZIL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 198. BRAZIL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 199. ARGENTINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 200. ARGENTINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ENDOVASCULAR PROCEDURES, 2018-2030 (USD MILLION)
TABLE 201. ARGENTINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ANGIOPLASTY, 2018-2030 (USD MILLION)
TABLE 202. ARGENTINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY, 2018-2030 (USD MILLION)
TABLE 203. ARGENTINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTING, 2018-2030 (USD MILLION)
TABLE 204. ARGENTINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 205. ARGENTINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 206. ARGENTINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 207. ARGENTINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BYPASS SURGERY, 2018-2030 (USD MILLION)
TABLE 208. ARGENTINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 209. ARGENTINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY DEVICES, 2018-2030 (USD MILLION)
TABLE 210. ARGENTINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BALLOONS, 2018-2030 (USD MILLION)
TABLE 211. ARGENTINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2030 (USD MILLION)
TABLE 212. ARGENTINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTS, 2018-2030 (USD MILLION)
TABLE 213. ARGENTINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, 2018-2030 (USD MILLION)
TABLE 214. ARGENTINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 215. ARGENTINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, 2018-2030 (USD MILLION)
TABLE 216. ARGENTINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 217. ARGENTINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SPECIALTY VASCULAR CENTERS, 2018-2030 (USD MILLION)
TABLE 218. ARGENTINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. ARGENTINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 220. ARGENTINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ENDOVASCULAR PROCEDURES, 2018-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ANGIOPLASTY, 2018-2030 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY, 2018-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTING, 2018-2030 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BYPASS SURGERY, 2018-2030 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY DEVICES, 2018-2030 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BALLOONS, 2018-2030 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2030 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTS, 2018-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, 2018-2030 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, 2018-2030 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SPECIALTY VASCULAR CENTERS, 2018-2030 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 244. UNITED KINGDOM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 245. UNITED KINGDOM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ENDOVASCULAR PROCEDURES, 2018-2030 (USD MILLION)
TABLE 246. UNITED KINGDOM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ANGIOPLASTY, 2018-2030 (USD MILLION)
TABLE 247. UNITED KINGDOM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY, 2018-2030 (USD MILLION)
TABLE 248. UNITED KINGDOM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTING, 2018-2030 (USD MILLION)
TABLE 249. UNITED KINGDOM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 250. UNITED KINGDOM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 251. UNITED KINGDOM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 252. UNITED KINGDOM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BYPASS SURGERY, 2018-2030 (USD MILLION)
TABLE 253. UNITED KINGDOM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 254. UNITED KINGDOM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY DEVICES, 2018-2030 (USD MILLION)
TABLE 255. UNITED KINGDOM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BALLOONS, 2018-2030 (USD MILLION)
TABLE 256. UNITED KINGDOM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2030 (USD MILLION)
TABLE 257. UNITED KINGDOM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTS, 2018-2030 (USD MILLION)
TABLE 258. UNITED KINGDOM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, 2018-2030 (USD MILLION)
TABLE 259. UNITED KINGDOM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 260. UNITED KINGDOM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, 2018-2030 (USD MILLION)
TABLE 261. UNITED KINGDOM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 262. UNITED KINGDOM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SPECIALTY VASCULAR CENTERS, 2018-2030 (USD MILLION)
TABLE 263. UNITED KINGDOM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 264. UNITED KINGDOM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 265. UNITED KINGDOM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 266. GERMANY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 267. GERMANY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ENDOVASCULAR PROCEDURES, 2018-2030 (USD MILLION)
TABLE 268. GERMANY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ANGIOPLASTY, 2018-2030 (USD MILLION)
TABLE 269. GERMANY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY, 2018-2030 (USD MILLION)
TABLE 270. GERMANY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTING, 2018-2030 (USD MILLION)
TABLE 271. GERMANY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 272. GERMANY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2030 (USD MILLION)
TABLE 273. GERMANY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 274. GERMANY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BYPASS SURGERY, 2018-2030 (USD MILLION)
TABLE 275. GERMANY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 276. GERMANY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ATHERECTOMY DEVICES, 2018-2030 (USD MILLION)
TABLE 277. GERMANY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY BALLOONS, 2018-2030 (USD MILLION)
TABLE 278. GERMANY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2030 (USD MILLION)
TABLE 279. GERMANY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STENTS, 2018-2030 (USD MILLION)
TABLE 280. GERMANY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, 2018-2030 (USD MILLION)
TABLE 281. GERMANY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 282. GERMANY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, 2018-2030 (USD MILLION)
TABLE 283. GERMANY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 284. GERMANY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SPECIALTY VASCULAR CENTERS, 2018-2030 (USD MILLION)
TABLE 285. GERMANY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 286. GERMANY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 287. GERMANY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 288. FRANCE CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZ

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Critical Limb Ischemia Treatment market report include:
  • Boston Scientific Corporation
  • Medtronic plc
  • Abbott Laboratories
  • LimFlow SA
  • Terumo Corporation
  • Cynata Therapeutics Ltd
  • Becton, Dickinson and Company
  • Penumbra, Inc.

Table Information

Report AttributeDetails
No. of Pages180
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 4.87 Billion
Forecasted Market Value ( USD ) by 2030 $ 7.45 Billion
Compound Annual Growth Rate8.9%
Regions CoveredGlobal
No. of Companies Mentioned9

Related Topics

Related Reports

Critical Limb Ischemia Treatment Market - Global Industry Size, Share, Trends Opportunity, and Forecast, 2020-2030F - Product Image

Critical Limb Ischemia Treatment Market - Global Industry Size, Share, Trends Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Critical Limb Ischemia Treatment - Global Strategic Business Report - Product Image

Critical Limb Ischemia Treatment - Global Strategic Business Report

  • Report
  • 375 Pages
  • Global
From
Critical Limb Ischemia Market Report 2025 - Product Image

Critical Limb Ischemia Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Critical Limb Ischemia - Pipeline Insight, 2025 - Product Image

Critical Limb Ischemia - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Peripheral Arterial Disease (PAD)- Pipeline Insight, 2025 - Product Image

Peripheral Arterial Disease (PAD)- Pipeline Insight, 2025

  • Clinical Trials
  • 80 Pages
  • Global
From

About the Critical Limb Ischemia Drug Market

Critical Limb Ischemia (CLI) is a severe form of peripheral artery disease (PAD) that affects the lower extremities. It is caused by a narrowing of the arteries that supply blood to the legs, leading to a lack of oxygen and nutrients to the affected area. CLI can lead to severe pain, ulcers, and even amputation. The CLI drug market is a subset of the larger cardiovascular drug market. It is composed of drugs that are used to treat CLI, such as anticoagulants, antiplatelet agents, and vasodilators. These drugs are used to reduce the risk of further narrowing of the arteries, reduce pain, and improve blood flow to the affected area. The CLI drug market is highly competitive, with many companies offering a variety of drugs. Some of the major players in the market include Pfizer, Merck, Sanofi, Bristol-Myers Squibb, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.